JUNIPER Disappoints But Lilly Continues With Abemaciclib In Different Combos, Cancers

Lilly's top-line Phase III JUNIPER data for abemaciclib in KRAS-mutated advanced non-small cell lung cancer may have disappointed, but the big pharma has vowed to continue evaluating the agent in this and in other cancers, and in combination therapies.